Quick Answer
Lucid Diagnostics Inc. reported Stockholders Equity of $10.94 million for the year ending 2025.
- Lucid Diagnostics Inc. showed an increase of +102.9% in Stockholders Equity from 2024 to 2025.
- This data is from Lucid Diagnostics Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$8.80 million | Q3 2020: -$10.80 million | Q1 2021: -$16.37 million | Q2 2021: -$19.95 million | Q3 2021: -$24.13 million | Q1 2022: $46.49 million | Q2 2022: $36.24 million | Q3 2022: $27.53 million | Q1 2023: $24.91 million | Q2 2023: $15.07 million | Q3 2023: $2.56 million | Q1 2024: $11.89 million | Q2 2024: $15.98 million | Q3 2024: $6.34 million | Q1 2025: -$5.38 million | Q2 2025: $7.86 million | Q3 2025: $25.84 million.
- Over the full 7 years of available data (2019 to 2025), Lucid Diagnostics Inc.'s Stockholders Equity has grown by 306.0%.
- Historical annual values: Fiscal year 2025: $10.94 million | Fiscal year 2024: $5.39 million | Fiscal year 2023: -$2.31 million | Fiscal year 2022: $23.05 million | Fiscal year 2021: $54.74 million | Fiscal year 2020: -$13.52 million | Fiscal year 2019: -$5.31 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: